Fred Hassan - 19 May 2022 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role
Director
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Fred Hassan
Issuer symbol
N/A
Transactions as of
19 May 2022
Net transactions value
$0
Form type
4
Filing time
20 May 2022, 19:20:04 UTC
Previous filing
29 Mar 2022
Next filing
24 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Award $0 +21,013 $0.000000 21,013 19 May 2022 Common Stock 21,013 $29.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.